CL2017000026A1 - Formas de dosificación farmacéutica - Google Patents

Formas de dosificación farmacéutica

Info

Publication number
CL2017000026A1
CL2017000026A1 CL2017000026A CL2017000026A CL2017000026A1 CL 2017000026 A1 CL2017000026 A1 CL 2017000026A1 CL 2017000026 A CL2017000026 A CL 2017000026A CL 2017000026 A CL2017000026 A CL 2017000026A CL 2017000026 A1 CL2017000026 A1 CL 2017000026A1
Authority
CL
Chile
Prior art keywords
pharmaceutical dosage
dosage forms
forms
pirrolo
dihidro
Prior art date
Application number
CL2017000026A
Other languages
English (en)
Inventor
Stefania Beato
Peggy Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017000026A1 publication Critical patent/CL2017000026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A FORMAS DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL QUE COMPRENDEN EL FÁRMACO 4-[(5R)-6,7-DIHIDRO-5H-PIRROLO[1,2-C]IMIDAZOL-5-IL]-3-FLUOROBENZONITRILO O CUALQUIER SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y A PROCESOS PARA PRODUCIR DICHAS FORMAS SÓLIDAS DE DOSIFICACIÓN FARMACÉUTICA.</p>
CL2017000026A 2014-07-07 2017-01-06 Formas de dosificación farmacéutica CL2017000026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462021271P 2014-07-07 2014-07-07

Publications (1)

Publication Number Publication Date
CL2017000026A1 true CL2017000026A1 (es) 2017-07-28

Family

ID=53610933

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000026A CL2017000026A1 (es) 2014-07-07 2017-01-06 Formas de dosificación farmacéutica

Country Status (29)

Country Link
US (2) US10143680B2 (es)
EP (2) EP3412278A1 (es)
JP (2) JP6731136B2 (es)
KR (1) KR102468610B1 (es)
CN (1) CN106470704B (es)
AR (1) AR101116A1 (es)
AU (1) AU2015287336B2 (es)
BR (1) BR112016030243B1 (es)
CA (1) CA2954393C (es)
CL (1) CL2017000026A1 (es)
CY (1) CY1120749T1 (es)
DK (1) DK3166596T3 (es)
EA (2) EA201991359A1 (es)
EC (1) ECSP17008187A (es)
ES (1) ES2686704T3 (es)
HR (1) HRP20181406T1 (es)
HU (1) HUE039037T2 (es)
IL (1) IL249374B (es)
LT (1) LT3166596T (es)
MX (1) MX2016017315A (es)
PE (1) PE20170201A1 (es)
PH (1) PH12016502540B1 (es)
PL (1) PL3166596T3 (es)
PT (1) PT3166596T (es)
SG (1) SG11201610227TA (es)
SI (1) SI3166596T1 (es)
TN (1) TN2016000557A1 (es)
TW (1) TWI707682B (es)
WO (1) WO2016005880A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532056A1 (en) 2016-10-27 2019-09-04 Damian Pharma AG Aldosterone synthase inhibitor
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191487A1 (en) 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2008114800A2 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
AU2011205290C1 (en) 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent
NZ607494A (en) * 2010-08-27 2015-04-24 Vertex Pharma Pharmaceutical composition and administrations thereof
JP6280501B2 (ja) * 2011-09-08 2018-02-14 メレオ バイオファーマ ２ リミテッド 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用
IN2014DN06781A (es) * 2012-01-17 2015-05-22 Novartis Ag
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
AU2013246908B2 (en) * 2012-04-12 2016-06-30 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Also Published As

Publication number Publication date
EA201790140A1 (ru) 2017-05-31
KR102468610B1 (ko) 2022-11-21
SI3166596T1 (sl) 2018-10-30
CN106470704B (zh) 2020-07-31
WO2016005880A1 (en) 2016-01-14
CA2954393C (en) 2022-07-19
KR20170029491A (ko) 2017-03-15
PT3166596T (pt) 2018-10-19
AR101116A1 (es) 2016-11-23
JP2017520590A (ja) 2017-07-27
CY1120749T1 (el) 2019-12-11
IL249374B (en) 2021-09-30
EP3166596B1 (en) 2018-06-06
MX2016017315A (es) 2017-04-27
DK3166596T3 (en) 2018-09-10
ECSP17008187A (es) 2018-03-31
TW201613586A (en) 2016-04-16
TWI707682B (zh) 2020-10-21
EP3166596A1 (en) 2017-05-17
PE20170201A1 (es) 2017-04-08
JP6731136B2 (ja) 2020-07-29
HRP20181406T1 (hr) 2018-10-19
US10709691B2 (en) 2020-07-14
PL3166596T3 (pl) 2018-11-30
TN2016000557A1 (en) 2018-04-04
PH12016502540B1 (en) 2022-07-20
JP2019194221A (ja) 2019-11-07
ES2686704T3 (es) 2018-10-19
US20190060283A1 (en) 2019-02-28
CA2954393A1 (en) 2016-01-14
BR112016030243B1 (pt) 2023-04-11
EP3412278A1 (en) 2018-12-12
SG11201610227TA (en) 2017-01-27
CN106470704A (zh) 2017-03-01
AU2015287336B2 (en) 2018-06-14
AU2015287336A1 (en) 2017-01-12
HUE039037T2 (hu) 2018-12-28
LT3166596T (lt) 2018-09-25
US20170202808A1 (en) 2017-07-20
IL249374A0 (en) 2017-02-28
EA201991359A1 (ru) 2020-03-13
EA033685B1 (ru) 2019-11-15
BR112016030243A2 (pt) 2017-08-22
US10143680B2 (en) 2018-12-04
PH12016502540A1 (en) 2017-04-10

Similar Documents

Publication Publication Date Title
MX2016013050A (es) Compuestos organicos.
MX2016013046A (es) Compuestos organicos.
MX2018009158A (es) Compuestos organicos.
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112017028140A2 (pt) formulações farmacêuticas
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
UY36124A (es) Derivados de carboxamida
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
ECSP17008187A (es) Formas de dosificación farmacéutica
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
EP3697393A4 (en) DOSAGE FORMS
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas